Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; magnesium stearate; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; carmellose sodium - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. diabex xr 500, diabex xr 750 or diabex xr 1000 may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - zonisamide, quantity: 100 mg - capsule, hard - excipient ingredients: allura red ac; sodium lauryl sulfate; hydrogenated vegetable oil; titanium dioxide; microcrystalline cellulose; sunset yellow fcf; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated. - adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - zonisamide, quantity: 50 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; sodium lauryl sulfate; gelatin; iron oxide black; hydrogenated vegetable oil; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated. - adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - zonisamide, quantity: 25 mg - capsule, hard - excipient ingredients: gelatin; microcrystalline cellulose; hydrogenated vegetable oil; titanium dioxide; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated. - adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; carmellose sodium - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. diabex xr 500 may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; carmellose sodium - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. diabex xr 500 may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

healol pharmaceuticals sdn. bhd. - glimepiride; metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; copovidone; magnesium stearate; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin